HomeNews

India Pharmaceutical Forum 2017

Jump to

Lupin's growth in US to stay muted next year

Speaking from the sidelines of the India Pharmaceutical Forum 2017, Lupin's Managing Director Nilesh Gupta shared his outlook on Indian industry and API inspections.
See commitment from Indian pharma to address concerns: MHRA

India is the key supplier of generic medicines to both US and UK and other parts of Europe. So, it is not surprising that the focus is on India, said Gerald W Heddell, Director-Inspection, Medicines and Healthcare products Regulatory Agency (MHRA).

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

India Pharmaceutical Forum 2017

Lupin's growth in US to stay muted next year

See commitment from Indian pharma to address concerns: MHRA